嵌合抗原受体 T 细胞疗法治疗癌症：小众疗法还是治疗模式？
Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?
机构信息
Department of Melanoma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
出版信息
Clin Cancer Res. 2013 Sep 1;19(17):4550-2. doi: 10.1158/1078-0432.CCR-13-1367. Epub 2013 Aug 6.
Abstract
Adoptive cellular therapy, involving the ex vivo enrichment and expansion of antigen-specific immune cells for adoptive transfer, has emerged as an increasingly effective modality for the treatment of patients with advanced cancer refractory to conventional therapy.
摘要
过继细胞疗法，包括体外抗原特异性免疫细胞的富集和扩增，以进行过继转移，已成为治疗对常规治疗无效的晚期癌症患者的一种越来越有效的方法。
相似文献
1
Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?嵌合抗原受体 T 细胞疗法治疗癌症：小众疗法还是治疗模式？
Clin Cancer Res. 2013 Sep 1;19(17):4550-2. doi: 10.1158/1078-0432.CCR-13-1367. Epub 2013 Aug 6.
2
IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.吲哚胺2,3-双加氧酶（IDO）和半乳糖凝集素-3阻碍了转移性黑色素瘤过继性细胞治疗中临床级肿瘤特异性T细胞的体外生成。
Cancer Immunol Immunother. 2017 Jul;66(7):913-926. doi: 10.1007/s00262-017-1995-x. Epub 2017 Apr 11.
3
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.转移性黑色素瘤患者肿瘤浸润淋巴细胞的过继转移：既往免疫治疗失败后的意向治疗分析和疗效。
Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20.
4
Adoptive T cell therapy: An overview of obstacles and opportunities.过继性T细胞疗法：障碍与机遇概述
Cancer. 2017 Jun 1;123(S11):2154-2162. doi: 10.1002/cncr.30491.
5
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.过继性 T 细胞疗法使用自体肿瘤浸润淋巴细胞治疗转移性黑色素瘤：现状与展望。
Cancer J. 2012 Mar-Apr;18(2):160-75. doi: 10.1097/PPO.0b013e31824d4465.
6
Tumor-infiltrating lymphocytes in melanoma.黑色素瘤中的肿瘤浸润淋巴细胞。
Curr Oncol Rep. 2012 Oct;14(5):468-74. doi: 10.1007/s11912-012-0257-5.
7
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.肿瘤浸润淋巴细胞过继转移治疗黑色素瘤：一种可行的治疗选择。
J Immunother Cancer. 2018 Oct 3;6(1):102. doi: 10.1186/s40425-018-0391-1.
8
Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.头颈部鳞状细胞癌患者 T 细胞的双模态体外扩增：过继细胞转移的前提条件。
Cytotherapy. 2011 Aug;13(7):822-34. doi: 10.3109/14653249.2011.563291. Epub 2011 Mar 24.
9
Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma.靶向不同基因产物的过继性 T 细胞治疗揭示了黑色素瘤中多样且依赖于背景的免疫逃逸。
Immunity. 2020 Sep 15;53(3):564-580.e9. doi: 10.1016/j.immuni.2020.07.007. Epub 2020 Aug 3.
10
Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.从皮肤和眼黑素瘤患者的循环肿瘤浸润 T 细胞中体外富集：过继细胞转移治疗的临床意义。
Cancer Immunol Immunother. 2012 Aug;61(8):1169-82. doi: 10.1007/s00262-011-1179-z. Epub 2011 Dec 30.
引用本文的文献
1
The Tumor Immune Environment: Advances in the Cancer Immunotherapy Era.肿瘤免疫微环境：癌症免疫治疗时代的进展
Methods Mol Biol. 2025;2926:15-34. doi: 10.1007/978-1-0716-4542-0_2.
2
When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies.当肿瘤免疫疗法遇上冷大气等离子体：对嵌合抗原受体T细胞（CAR-T）疗法的影响
Front Oncol. 2022 Feb 23;12:837995. doi: 10.3389/fonc.2022.837995. eCollection 2022.
3
A biomimetic antitumor nanovaccine based on biocompatible calcium pyrophosphate and tumor cell membrane antigens.一种基于生物相容性焦磷酸钙和肿瘤细胞膜抗原的仿生抗肿瘤纳米疫苗。
Asian J Pharm Sci. 2021 Jan;16(1):97-109. doi: 10.1016/j.ajps.2020.06.006. Epub 2020 Jul 27.
4
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?迎接癌症免疫治疗挑战：双特异性抗体，前行之路？
Antibodies (Basel). 2015 Dec 26;5(1):1. doi: 10.3390/antib5010001.
5
Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.使用靶向 PD-1/PD-L1 通路的 PolyPurine Reverse Hoogsteen 发夹的癌症免疫疗法在人类肿瘤细胞中。
PLoS One. 2018 Nov 6;13(11):e0206818. doi: 10.1371/journal.pone.0206818. eCollection 2018.
6
The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams.人类药物研发团队中具备医学资质和不具备医学资质的专家的共同道德责任。
Front Pharmacol. 2018 Sep 3;9:843. doi: 10.3389/fphar.2018.00843. eCollection 2018.
7
Methods of Controlling Invasive Fungal Infections Using CD8 T Cells.利用CD8 T细胞控制侵袭性真菌感染的方法。
Front Immunol. 2018 Jan 8;8:1939. doi: 10.3389/fimmu.2017.01939. eCollection 2017.
8
A Synthetic CD8α:MyD88 Coreceptor Enhances CD8 T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens.一种合成的CD8α:MyD88共受体增强CD8 T细胞对弱免疫原性和低表达肿瘤抗原的反应。
Cancer Res. 2017 Dec 15;77(24):7049-7058. doi: 10.1158/0008-5472.CAN-17-0653. Epub 2017 Oct 20.
9
Cellular immunity augmentation in mainstream oncologic therapy.主流肿瘤治疗中的细胞免疫增强
Cancer Biol Med. 2017 May;14(2):121-128. doi: 10.20892/j.issn.2095-3941.2017.0022.
10
Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.利用癌症特异性复制：溶瘤病毒作为增强癌症免疫治疗策略的通用平台
Biomedicines. 2016 Aug 24;4(3):21. doi: 10.3390/biomedicines4030021.
本文引用的文献
1
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.转移性黑色素瘤患者肿瘤浸润淋巴细胞的过继转移：既往免疫治疗失败后的意向治疗分析和疗效。
Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20.
2
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性淋巴细胞白血病。
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
3
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.特异性淋巴细胞亚群预测转移性黑色素瘤患者接受扩增自体肿瘤浸润淋巴细胞过继细胞治疗的反应。
Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.
4
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
5
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.转移的黑色素瘤特异性 CD8+ T 细胞持续存在，介导肿瘤消退，并获得中央记忆表型。
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4592-7. doi: 10.1073/pnas.1113748109. Epub 2012 Mar 5.
6
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.利用体外培养的 CD8+ T 细胞在人体内建立抗肿瘤记忆。
Sci Transl Med. 2011 Apr 27;3(80):80ra34. doi: 10.1126/scitranslmed.3002207.
7
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.采用 T 细胞转移免疫疗法治疗转移性黑色素瘤的大量预处理患者中持久的完全应答。
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116. Epub 2011 Apr 15.
8
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.经过最低限度培养的肿瘤浸润淋巴细胞表现出用于过继性细胞治疗的最佳特性。
J Immunother. 2008 Oct;31(8):742-51. doi: 10.1097/CJI.0b013e31818403d5.
9
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.用针对NY-ESO-1的自体CD4+ T细胞治疗转移性黑色素瘤。
N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251.
10
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.白细胞介素-21影响抗原特异性CD8 T细胞反应的频率、表型和亲和力。
J Immunol. 2005 Aug 15;175(4):2261-9. doi: 10.4049/jimmunol.175.4.2261.
Zotero 插件